---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-26-408287"
form_type: "8-K"
ticker: "JBIO"
cik: "0001798749"
company_name: "Jade Biosciences, Inc."
filed_at: "2026-09-30T11:13:31+00:00"
generated_at: "2026-10-12T13:57:12.952922+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.55
calibrated_materiality_score: 0.55
confidence: "high"
source: SEC EDGAR
---

# Jade Biosciences reports preclinical JADE301 data in dermatomyositis; Phase 1 in 24 healthy volunteers to start Q4 2026

## Summary
- JADE301 binds IFN-β with KD of 11.3 pM, ~2.5-fold higher affinity than the dazukibart comparator, with no detectable binding to other interferon family proteins.
- Inhibited pSTAT induction with IC50 of 13 pM (~2.5-fold more potent than dazukibart) and MX-1 in human dermal fibroblasts with IC50 of 11 pM (~8-fold more potent).
- NHP data: ~30-day half-life after 30 mg/kg IV (~3x longer than dazukibart) and ~25-day SC half-life; modeled human SC bioavailability ~73%-75% vs dazukibart's ~43%-44%.
- GLP NHP toxicology: SC JADE301 every two weeks at 0, 50, 100 and 200 mg/kg was well tolerated; no treatment-related adverse clinical, lab or histopathology findings.
- Phase 1 placebo-controlled single ascending-dose SC trial in 24 healthy volunteers to start Q4 2026; interim data anticipated in the second half of 2027.

## SEC filing metadata
- accession: 0001193125-26-408287
- form_type: 8-K
- ticker: JBIO
- cik: 0001798749
- company_name: Jade Biosciences, Inc.
- filed_at: 2026-09-30T11:13:31+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.55
- calibrated_materiality_score: 0.55
- confidence: high
- sec_items: 8.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1798749/000119312526408287/0001193125-26-408287-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1798749/000119312526408287/d936098d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-26-408287
- JSON: https://secwatch.observer/filing/0001193125-26-408287.json
- Plain text: https://secwatch.observer/filing/0001193125-26-408287.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.